Literature DB >> 1234801

Diagnosis and staging of ovarian carcinoma.

T G Day, J P Smith.   

Abstract

The early diagnosis of ovarian carcinoma will await the development of adequate and accurate screening tests. In the interval prior to development of these tests, ovarian cancers will frequently be discovered in an advanced stage. Improved methods of treatment must be based on an adequate trial of existing treatment methods founded on an understanding of factors influencing survival. FIGO stage grouping identifies many of these factors and should be used to identify patients with similar characteristics. Other prognostic factors such as tumor grade, volume of residual disease and the presence of ascites must be recorded and considered in evaluating therapeutic trials. The adoption of a routine method for patient evaluation and exploration may enhance the amount of information available for each patient and assure that adequate information is available with which to place the pateint in FIGO stage and substage.

Entities:  

Mesh:

Year:  1975        PMID: 1234801

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  4 in total

1.  The staging and treatment of epithelial ovarian cancer.

Authors:  R C Young; R I Fisher
Journal:  Can Med Assoc J       Date:  1978-08-12       Impact factor: 8.262

2.  Preclinical evaluation of aclacinomycin A for the intraperitoneal treatment of human ovarian carcinoma.

Authors:  K G Louie; T C Hamilton; B C Behrens; K R Grotzinger; W M McKoy; C E Myers; R C Young; R F Ozols
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  High dose cisplatin compared with high dose cyclophosphamide in the management of advanced epithelial ovarian cancer (FIGO stages III and IV): report from the North Thames Cooperative Group.

Authors:  H E Lambert; R J Berry
Journal:  Br Med J (Clin Res Ed)       Date:  1985-03-23

4.  Abdominopelvic washings: A comprehensive review.

Authors:  Erika F Rodriguez; Sara E Monaco; Walid Khalbuss; R Marshall Austin; Liron Pantanowitz
Journal:  Cytojournal       Date:  2013-04-24       Impact factor: 2.091

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.